These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 11103757

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Absence of a pharmacokinetic interaction between etanercept and warfarin.
    Zhou H, Patat A, Parks V, Buckwalter M, Metzger D, Korth-Bradley J.
    J Clin Pharmacol; 2004 May; 44(5):543-50. PubMed ID: 15102876
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Reply to rebuttal: Gene variants of the cytochrome P450 CYP2C9 affect oral anticoagulation with warfarin.
    Margaglione M, Brancaccio V, Ciampa A, Di Minno G.
    Thromb Haemost; 2001 Sep; 86(3):938. PubMed ID: 11583336
    [No Abstract] [Full Text] [Related]

  • 13. Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro study.
    Burstein AH, Clark DJ, O'Gorman M, Willavize SA, Brayman TG, Grover GS, Walsky RL, Obach RS, Faessel HM.
    J Clin Pharmacol; 2007 Nov; 47(11):1421-9. PubMed ID: 17962429
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.
    Schwartz JI, Dunbar S, Yuan J, Li S, Gipson A, Rosko K, Johnson-Levonas AO, Lasseter KC, Addy C, Stoch AS, Wagner JA.
    Adv Ther; 2008 Nov; 25(11):1175-90. PubMed ID: 18989636
    [Abstract] [Full Text] [Related]

  • 16. Pharmacogenetics of warfarin elimination and its clinical implications.
    Takahashi H, Echizen H.
    Clin Pharmacokinet; 2001 Nov; 40(8):587-603. PubMed ID: 11523725
    [Abstract] [Full Text] [Related]

  • 17. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics.
    Simonson SG, Martin PD, Mitchell PD, Lasseter K, Gibson G, Schneck DW.
    J Clin Pharmacol; 2005 Aug; 45(8):927-34. PubMed ID: 16027403
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766.
    Oberwittler H, Hirschfeld-Warneken A, Wesch R, Willerich H, Teichert L, Lehr KH, Ding R, Haefeli WE, Mikus G.
    J Clin Pharmacol; 2007 Jan; 47(1):70-7. PubMed ID: 17192504
    [Abstract] [Full Text] [Related]

  • 20. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
    D'Angelo A, Della Valle P, Crippa L, Fattorini A, Pattarini E, Viganò D'Angelo S.
    Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.